Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 liquidated — weigh against the wins.
1 vehicle on file, newest listing first
none appears on more than one
John Maslowski , 51, is a director. Mr. Maslowski has served as President and Chief Executive Officer of Forge Biologics since October 2024 and has served as a member of its board of directors since October 2024. Prior to that, Mr. Maslowski served as Chief Commercial Officer of Forge Biologics from June 2021 to October 2024. Mr. Maslowski previously served as President and Chief Executive Officer of Castle Creek Biosciences, Inc. from January 2020 to May 2021 and as Chief Scientific Advisor from May 2021 to December 2021. Mr. Maslowski also served as President and Chief Executive Officer of Fibrocell Science, Inc. (Nasdaq: FCSC, acquired by Castle Creek Pharmaceutical Holdings, Inc.) from December 2016 to January 2020. Mr. Maslowski currently serves on the board of directors of Nionyx Bio and debra of America, and he previously served on the board of directors of the Alliance for Regenerative Medicine and Castle Creek Biosciences, Inc. Mr. Maslowski holds an M.S. in Microbiology from Villanova University and a B.S. in Biology from Ursinus College. We believe that Mr.
This record is keyed to SEC CIK 0001608774 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 5 institutional-holder rows on these vehicles, under 5 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.